New Therapies of Neovascular AMD beyond Anti-VEGF Injections.
| Autor: | Gahn GM; University of Nevada, Reno School of Medicine, Reno, NV 89557, USA., Khanani AM; Sierra Eye Associates, Reno, NV 89502, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Vision (Basel, Switzerland) [Vision (Basel)] 2018 Mar 19; Vol. 2 (1). Date of Electronic Publication: 2018 Mar 19. |
| DOI: | 10.3390/vision2010015 |
| Abstrakt: | Neovascular age-related macular degeneration is a leading cause of vision loss among the aging population. The current standard of care to treat neovascular age-related macular degeneration is inhibiting vascular endothelial growth factor (VEGF) through intravitreal injections. Recent studies have demonstrated that the tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 2 (Tie2) pathway also plays a critical role in angiogenesis and vascular stability. Additionally, newly developed treatment delivery systems have been designed to greatly reduce the frequency of injections. In targeting the Tie2 pathway and utilizing a sustained release delivery system, patients may experience improved visual outcomes and a reduced burden of treatment. Competing Interests: Greggory M. Gahn—has no conflicts of interest to report; Arshad M. Khanani: consultant for Genentech/Roche, receives research funding from Genentech/Roche and is a speaker for Genentech. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|